Skip to main content
Erschienen in: Breast Cancer 4/2020

29.02.2020 | Original Article

Epidemiology and biological characteristics of male breast cancer in Italy

verfasst von: Lucia Mangone, Francesca Ferrari, Pamela Mancuso, Giuliano Carrozzi, Maria Michiara, Fabio Falcini, Silvano Piffer, Rosa Angela Filiberti, Adele Caldarella, Francesco Vitale, Rosario Tumino, Angelita Brustolin, Giovanna Tagliabue, Paolo Giorgi Rossi, Laura Ottini

Erschienen in: Breast Cancer | Ausgabe 4/2020

Einloggen, um Zugang zu erhalten

Abstract

Aim

To evaluate the epidemiology of male breast cancer (MBC) in Italy and to describe incidence and survival data in relation to age, morphology, year of incidence, geographic area, and possible association with other cancers compared with female BC.

Methods

Cases were extracted from 40 Italian Cancer Registries. Standardized incidence rates (SIR), age-specific rates, and 5-year survival were calculated. The association with second tumors was also evaluated. All data were compared with data from female BCs.

Results

In the 2000–2014 period, 2175 new cases of MBC were registered, with an SIR of 1.7 × 100,000. The incidence showed a slight upward trend and increased with increasing age. The 5-year survival was 82% in the first two periods (2000–2004, 2005–2009), lower than in females (87%). The most frequent morphology was the ductal carcinoma (84%). Stage at diagnosis was 39.5% stage I, 33.1% stage II, 20.9% in stage III, and 6.4% in stage IV. Concerning receptor status, 96.4% had ER+ and 82.5% PR+; 46.5% had high Ki67 and 14.7% HER2 amplified. The risk of BC increased if the man had already had a previous tumor in any site (excess absolute risk, EAR = 2.7) and especially if he had had prostate cancer (EAR = 5.1). Instead, males with a previous diagnosis of BC had an increased risk of testicular, kidney and lung cancer.

Conclusions

MBC requires more attention in terms of diagnosis and treatment as clinicians tend to follow the guidelines that have been developed for female BC management.
Literatur
1.
Zurück zum Zitat Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232–9.PubMed Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a population-based comparison with female breast cancer. J Clin Oncol. 2010;28(2):232–9.PubMed
2.
Zurück zum Zitat AIOM, AIRTUM, Fondazione AIOM, PASSI. I numeri del cancro in Italia 2018, Intermedia Editore; 2018. AIOM, AIRTUM, Fondazione AIOM, PASSI. I numeri del cancro in Italia 2018, Intermedia Editore; 2018.
3.
Zurück zum Zitat Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer—a case–control study from Scandinavia. Acta Oncol. 2001;40(4):467–71.PubMed Ewertz M, Holmberg L, Tretli S, Pedersen BV, Kristensen A. Risk factors for male breast cancer—a case–control study from Scandinavia. Acta Oncol. 2001;40(4):467–71.PubMed
4.
Zurück zum Zitat Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22(4):735–42 (review).PubMed Liede A, Karlan BY, Narod SA. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol. 2004;22(4):735–42 (review).PubMed
5.
Zurück zum Zitat Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114–222.PubMedPubMedCentral Korde LA, Zujewski JA, Kamin L, Giordano S, Domchek S, Anderson WF, et al. Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010;28(12):2114–222.PubMedPubMedCentral
6.
Zurück zum Zitat Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother. 2007;8(2):193–202 (review).PubMed Cutuli B. Strategies in treating male breast cancer. Expert Opin Pharmacother. 2007;8(2):193–202 (review).PubMed
8.
Zurück zum Zitat Buzzoni C, Crocetti E, Bella F, Bonelli L, Caldarella A, Castaing M, et al. I tumori in Italia—Rapporto 2013, Tumori multipli. Epidemiol Prev. 2013;37(4–5 Suppl 1):1–152. Buzzoni C, Crocetti E, Bella F, Bonelli L, Caldarella A, Castaing M, et al. I tumori in Italia—Rapporto 2013, Tumori multipli. Epidemiol Prev. 2013;37(4–5 Suppl 1):1–152.
10.
Zurück zum Zitat Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009;45(18):3166–71.PubMed Puliti D, Zappa M, Miccinesi G, Falini P, Crocetti E, Paci E. An estimate of overdiagnosis 15 years after the start of mammographic screening in Florence. Eur J Cancer. 2009;45(18):3166–71.PubMed
11.
Zurück zum Zitat Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405–17.PubMed Cardoso F, Bartlett JMS, Slaets L, van Deurzen CHM, van Leeuwen-Stok E, Porter P, et al. Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Ann Oncol. 2018;29(2):405–17.PubMed
12.
Zurück zum Zitat Rizzolo P, Zelli V, Silvestri V, Valentini V, Zanna I, Bianchi S, et al. Insight into genetic susceptibility to male breast cancer by multigene panel testing: results from a multicenter study in Italy. Int J Cancer. 2019;145(2):390–400.PubMed Rizzolo P, Zelli V, Silvestri V, Valentini V, Zanna I, Bianchi S, et al. Insight into genetic susceptibility to male breast cancer by multigene panel testing: results from a multicenter study in Italy. Int J Cancer. 2019;145(2):390–400.PubMed
14.
Zurück zum Zitat Silvestri V, Zelli V, Valentini V, Rizzolo P, Navazio AS, Coppa A, et al. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer. 2017;123(2):210–8.PubMed Silvestri V, Zelli V, Valentini V, Rizzolo P, Navazio AS, Coppa A, et al. Whole-exome sequencing and targeted gene sequencing provide insights into the role of PALB2 as a male breast cancer susceptibility gene. Cancer. 2017;123(2):210–8.PubMed
15.
Zurück zum Zitat Humphries MP, Sundara Rajan S, Honarpisheh H, Cserni G, Dent J, Fulford L, et al. Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Sci Rep. 2017;28(7):45293. Humphries MP, Sundara Rajan S, Honarpisheh H, Cserni G, Dent J, Fulford L, et al. Characterisation of male breast cancer: a descriptive biomarker study from a large patient series. Sci Rep. 2017;28(7):45293.
16.
Zurück zum Zitat Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, et al. A possible role of FANCM mutations in male breast cancer susceptibility: results from a multicenter study in Italy. Breast. 2018;38:92–7.PubMed Silvestri V, Rizzolo P, Zelli V, Valentini V, Zanna I, Bianchi S, et al. A possible role of FANCM mutations in male breast cancer susceptibility: results from a multicenter study in Italy. Breast. 2018;38:92–7.PubMed
17.
Zurück zum Zitat Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, et al. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol. 2013;24(Suppl 8):viii75–viii82.PubMed Rizzolo P, Silvestri V, Tommasi S, Pinto R, Danza K, Falchetti M, et al. Male breast cancer: genetics, epigenetics, and ethical aspects. Ann Oncol. 2013;24(Suppl 8):viii75–viii82.PubMed
18.
Zurück zum Zitat Romaguera D, Lavedan E, Molinuevo A, de Batlle J, Mendez M, Moreno V, et al. Adherence to nutrition-based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the MCC-Spain case–control study. Int J Cancer. 2017;141(1):83–93. https://doi.org/10.1002/ijc.30722(Epub 2017 Apr 21).PubMed Romaguera D, Lavedan E, Molinuevo A, de Batlle J, Mendez M, Moreno V, et al. Adherence to nutrition-based cancer prevention guidelines and breast, prostate and colorectal cancer risk in the MCC-Spain case–control study. Int J Cancer. 2017;141(1):83–93. https://​doi.​org/​10.​1002/​ijc.​30722(Epub 2017 Apr 21).PubMed
Metadaten
Titel
Epidemiology and biological characteristics of male breast cancer in Italy
verfasst von
Lucia Mangone
Francesca Ferrari
Pamela Mancuso
Giuliano Carrozzi
Maria Michiara
Fabio Falcini
Silvano Piffer
Rosa Angela Filiberti
Adele Caldarella
Francesco Vitale
Rosario Tumino
Angelita Brustolin
Giovanna Tagliabue
Paolo Giorgi Rossi
Laura Ottini
Publikationsdatum
29.02.2020
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 4/2020
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-020-01068-1

Weitere Artikel der Ausgabe 4/2020

Breast Cancer 4/2020 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.